Givinostat (formerly ITF2357), an orally active HDAC inhibitor, has been shown to prevent the development of diabetes.84, 85 Similarly, activation of sirtuin1, which is involved in inflammation, metabolism, and aging, has been shown to have anti-inflammatory properties in diabetes.86 Here, HDAC9 is linked to diabetes mellitus.